Lusutrombopag (thrombocytopenia with chronic liver disease)

Subject:

• Active Substance: Lusutrombopag
• Name: Mulpleo^®
• Therapeutic area: Thrombocytopenia
• Pharmaceutical company: Shionogi GmbH

Time table:

• Start: 01.12.2021
• Final decision by G-BA: 19.05.2022

Final decision:

• No additional benefit proved